Stratum Biosciences获得 200万美元种子轮融资，以加速人工智能驱动的皮肤生物学发现及扩展研发合作伙伴关系-动脉网

Stratum Biosciences Secures $2M Seed Round to Accelerate AI-Powered Skin Biology Discovery and Expanded R&D Partnerships

PR Newswire 等信源发布 2026-03-27 20:36



可切换为仅中文







NEW YORK

纽约

，

March 27, 2026

2026年3月27日

/PRNewswire/ -- Stratum Biosciences, a biotechnology pioneer at the intersection of artificial intelligence and dermatology research, announced the closing of a $2M seed funding round backed by the Harvard Business School Alumni Angels of Greater New York and Skin Angels, the world's largest network of early-stage skin and dermatology investors..

/PRNewswire/ -- Stratum Biosciences，一家处于人工智能与皮肤病学研究交汇点的生物技术先锋企业，宣布完成了由哈佛商学院校友天使会（大纽约地区）和全球最大的早期皮肤与皮肤病学投资者网络Skin Angels支持的200万美元种子轮融资。

Stratum was co-founded in 2024 by dermatologist Dr. Ross Lane Pearlman and dermatopathologist Dr. Buu Duong, both leaders in their specialties for integrating technology and AI into skin research and workflows. The investment will be used to scale the company's proprietary AI-powered skin biology discovery platform, mining over 200,000 real skin samples for novel insights and translating findings into accelerated product development..

Stratum 由皮肤科医生罗斯·莱恩·珀尔曼博士和皮肤病理学家布杜昂博士于2024年共同创立，二人均为将技术与人工智能整合到皮肤研究和工作流程中的行业领导者。这笔投资将用于扩展公司专有的AI驱动的皮肤生物学发现平台，挖掘超过20万份真实皮肤样本以获取新颖见解，并将研究成果转化为加速的产品开发。

'As a dermatologist, I see every day that the biggest gap in skin innovation is our limited understanding of skin biology,' said Dr. Ross Pearlman, CEO and Co-founder of Stratum Biosciences. 'With modern AI, we can finally uncover the mechanisms hidden within skin that can translate into entirely new solutions to skin health.'.

“作为一名皮肤科医生，我每天都能看到皮肤创新领域最大的差距在于我们对皮肤生物学的理解有限，”Stratum Biosciences的首席执行官兼联合创始人罗斯·珀尔曼博士说道，“借助现代人工智能，我们终于可以揭示皮肤内隐藏的机制，从而转化为全新的皮肤健康解决方案。”

AI-Powered Research Paves the Way for Better Understanding of Skin

人工智能驱动的研究为更好地了解皮肤铺平了道路

Central to Stratum's expansion is participation in NVIDIA's Inception program, designed to nurture startups transforming industries through technological advancement. By leveraging NVIDIA's computing resources, Stratum plans to rapidly mine its proprietary skin biopsy database to identify novel biomarkers and insights that have previously eluded traditional research and development methods..

Stratum 扩张的核心是参与 NVIDIA 的 Inception 计划，该计划旨在扶持通过技术进步推动行业变革的初创企业。通过利用 NVIDIA 的计算资源，Stratum 计划快速挖掘其专有的皮肤活检数据库，以识别传统研发方法未能发现的新型生物标志物和洞察。

'Our skin is a window to our bodies, and Stratum's biobank holds the keys to new, undiscovered targets for anti-aging and beyond,' said Dr. Buu Duong, President and Co-founder. 'We now have the tools to unlock these insights and build solutions at scale. Beyond observational research, we are now decoding the skin's biological language to redefine how the industry approaches longevity and health.'.

“我们的皮肤是通往身体的窗口，而Stratum的生物样本库拥有抗衰老及其他领域新未开发目标的关键，”总裁兼联合创始人Buu Duong博士说道。“我们现在拥有了解锁这些洞察并大规模构建解决方案的工具。除了观察性研究，我们正在解码皮肤的生物学语言，重新定义行业对长寿和健康的探索方式。”

Stratum's SkinSync™ platform has already uncovered significant insights into the structure and function of skin that challenge long-held assumptions about the skin barrier.

Stratum的SkinSync™平台已经揭示了关于皮肤结构和功能的重要见解，这些见解挑战了长期以来对皮肤屏障的假设。

'The scientific progress this team has been able to make in such a short amount of time has been remarkable,' said Chief Scientific Officer Dr. David Osborne, former co-founder of Arcutis (ARQT).

“这个团队在如此短的时间内取得的科学进展令人瞩目，”首席科学官、Arcutis（ARQT）前联合创始人大卫·奥斯本博士表示。

'It's exciting to take my career experience and use the platform and methodology created by Stratum to rewrite our understanding of dermatology and fundamentally improve human skin care.'

“运用我在职业生涯中积累的经验，借助Stratum创建的平台和方法，重新改写我们对皮肤病学的理解，并从根本上改善人类的皮肤护理，这让我感到非常兴奋。”

Scaling the SkinSync™ Platform for Global Partnerships

扩展SkinSync™平台以实现全球合作伙伴关系

Over the past 12 months, Stratum Biosciences has successfully validated its approach by partnering with global CPG leaders and subsidiaries to develop novel composition-of-matter actives and formulations with optimized delivery systems and bioavailability using SkinSync™, Stratum's proprietary AI-powered discovery platform.

在过去的 12 个月里，Stratum Biosciences 通过与全球消费品包装领导者及其子公司合作，成功验证了其方法，利用其专有的人工智能驱动发现平台 SkinSync™，开发出具有优化递送系统和生物利用度的新型物质组成活性成分和配方。

Expected products target the most pressing needs in skincare and dermatology, including hyperpigmentation and skin longevity..

预计产品将针对护肤和皮肤病学中最紧迫的需求，包括色素沉着和皮肤长寿。

With this new funding, Stratum is rapidly building partnerships focused on skin biology discovery with translation into novel ingredient and formulation technology. Stratum is currently based out of Johnson and Johnson's accelerator in New York, JLabs@NYC, located in SoHo.

通过这笔新的资金，Stratum正在迅速建立专注于皮肤生物学发现的合作伙伴关系，并将其转化为新型成分和配方技术。Stratum目前位于纽约SoHo区的强生加速器JLabs@NYC。

About Stratum Biosciences

关于Stratum生物科学

Stratum Biosciences is a dermatology discovery company leveraging a proprietary AI platform and over 200,000 real tissue samples to accelerate development of novel active ingredients and formulations for cosmetic and pharmaceutical skin products.

Stratum Biosciences是一家皮肤病学研发公司，利用专有的人工智能平台和超过20万份真实组织样本，加速开发用于化妆品和药物皮肤产品的新型活性成分和配方。

A resident company of Johnson and Johnson's JLABs incubator, Stratum is solving some of skin's toughest challenges for global brands with a pipeline of high-value IP targeting diverse needs from skin longevity to hyperpigmentation and eczema.

作为强生公司JLABs孵化器的驻场公司，Stratum正通过一系列高价值知识产权解决全球品牌面临的皮肤难题，满足从皮肤延缓衰老到色斑和湿疹等多样化需求。

Media Contact:

媒体联系人：

Andres Berrios

安德烈斯·贝里奥斯

[email protected]

电子邮件地址

6468202641

www.stratumbio.com

SOURCE Stratum Biosciences

来源：Stratum Biosciences

more press release views with